Target intelligence / Profile preview

Patient-specific tumor neoantigen-specific T-cell receptor (NeoTCR) (NeoTCR)

Target
NeoTCR
Molecular classification
Receptor, T-cell receptor complex, Heterodimeric glycoprotein
01

Overview

Patient-specific tumor neoantigen-specific T-cell receptors (NeoTCRs) are specialized proteins engineered to recognize unique mutations, or neoantigens, present only in an individual patient's tumor cells [1]. These neoantigens result from somatic mutations that create novel protein sequences not found in the normal human genome, providing a highly specific target for the immune system [2]. In clinical applications, NeoTCRs are typically used in adoptive cell transfer (ACT) therapies, where a patient's T-cells are genetically modified to express a TCR that has been identified and validated to bind a specific neoepitope presented by the patient's Major Histocompatibility Complex (MHC) [3]. Upon re-infusion, these engineered T-cells circulate and infiltrate tumor sites, where the NeoTCR binds to its cognate antigen, triggering T-cell activation, proliferation, and the release of cytotoxic molecules like granzymes and perforins to kill the cancer cells [5]. This personalized approach is designed to minimize "off-target" damage to healthy tissues, as the target antigens are absent outside the tumor [1]. However, challenges remain, including the complex process of neoantigen identification, the potential for tumor escape through HLA downregulation, and the risk of cytokine-related toxicities [5]. Current research focuses on optimizing the identification of high-affinity TCRs and improving the persistence of the engineered cells within the immunosuppressive tumor microenvironment [2].

Other names
Neoantigen-specific T-cell receptorPersonalized TCRTumor-specific TCRNeo-TCRNeoantigen-reactive T-cell receptor
02

Mechanism of action

NeoTCRs function by binding to specific neoepitopes (mutated peptides) presented by the patient's HLA molecules on the tumor cell surface, which triggers the formation of an immunological synapse, T-cell signaling via the CD3 complex, and subsequent release of cytotoxic effectors like perforin and granzymes to induce apoptosis in the target cell [1, 5].

03

Biological functions

Immune responseAntigen recognitionCell-mediated cytotoxicityT-cell activation
04

Disease associations

CancerSolid tumorsMelanomaGastrointestinal cancerLung cancer
05

Safety considerations

Cytokine release syndrome (CRS)Immune effector cell-associated neurotoxicity syndrome (ICANS)On-target off-tumor toxicity due to shared epitopesGraft-versus-host diseaseTumor antigen escape
06

Interacting drugs

NT-112

2 more in the full profile.

07

Biomarkers

HLA-A*02:01 expressionTumor Mutational Burden (TMB)Neoantigen loadTCR expression densityCD8+ T-cell infiltration

Beyond the preview

Go deeper on Patient-specific tumor neoantigen-specific T-cell receptor (NeoTCR) (NeoTCR).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Patient-specific tumor neoantigen-specific T-cell receptor (NeoTCR) (NeoTCR).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call